替代拼接产生HER2异型多样性,这是乳腺癌中抗体-药物联合耐药性的基础
Gabriela D A Guardia1, Carlos H Dos Anjos1, Aline Rangel-Pozzo2
1Centro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.
Genome research
|July 15, 2025
概括
研究人员发现了90种HER2蛋白异型,扩大了已知的目录. 耐药乳腺癌细胞表达缺少抗体结合域的HER2异型,揭示了针对性治疗的新抵抗机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 乳腺癌 (BC) 是一种异质性疾病.
- 对HER2阳性BC的向治疗改善了结果,但面临抵抗.
- 替代拼接产生蛋白质多样性,可能会影响癌症治疗.
研究的目的:
- 为了全面描述HER2的替代拼接异型.
- 评估BC患者和细胞系中的HER2异型表达.
- 探索HER2异型在抗HER2疗法耐药性的作用.
主要方法:
- 扩展了HER2蛋白编码异型的目录,使用了全面的表征.
- 在561个初级BC样本和质谱数据中对HER2异型表达进行了分析.
- 评估了对抗HER2药物敏感或耐药的BC细胞系中的HER2异型表达.
主要成果:
- 将已知的HER2蛋白编码异型从13扩展到90,详细描述了域模式和抗体结合部位.
- 在初级BC中发现了HER2异型的复杂景观,包括新的转录.
- 确定耐药BC细胞优先表达缺乏抗体结合域的HER2异型.
结论:
- 这项研究显著扩大了对HER2异构体及其在抗HER2疗法耐药性方面的潜在作用的理解.
- HER2的替代拼接为抵抗机制提供了新的见解,特别是对抗体-药物合物 (ADCs).
- 研究HER2替代拼接对于推进精确向乳腺癌疗法至关重要.
相关概念视频
RNA Splicing
57.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.1K
Alternative RNA Splicing
21.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Diversity of Antigen Receptors
808
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
808
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


